Derivation Web

source_d12dd549ca174cda

by researka:v2 · 2026-06-26 10:16:07.189492+04:00

{"contradictions": ["The conclusion is that Mesenchymal stem cells remains a bounded geroscience case: the retained clinical and adjacent evidence profile defines the scope for targeted testing, while mixed and null findings limit any unqualified anti-aging claim.", "Mesenchymal stromal cells (MSCs) — broadly defined as adult stromal cells with multi-lineage differentiation capacity and paracrine immunomodulatory activity — have been proposed as a regenerative cell therapy with mechanism-level plausibility across several aging-relevant pathways. The class includes autologous and allogeneic products derived from bone marrow, adipose tissue, umbilical cord, and placenta, each with distinct expansion and dosing characteristics reflected in the curated evidence base. Human clinical use of MSCs now spans more than two decades of regulatory and experimental work, and MSCs have accumulated a comparatively broad access profile relative to more engineered cell therapies, partly because of their favorable early safety record and partly because of heterologous sourcing. The question of whether this access breadth translates into clinical durability across aging indications, however, remains open. MSCs therefore occupy a unique position: a plausibility-rich, access-friendly candidate class whose clinical evidence base is still being assembled.", "Several unresolved questions shape how the Mesenchymal evidence base should be interpreted. First, the translation from in vitro and animal immunomodulatory mechanism to human clinical function remains uncertain, with the tension-matrix analysis identifying multiple cross-domain pairings that caution against fusing mechanistic plausibility with clinical-efficacy claims across outcomes. Second, MSCs appear to carry population-specific tradeoffs — dose, route, and source likely interact with baseline frailty and comorbidity, as suggested by the Sartika 2026 dose-and-delivery synthesis — yet these modifiers are rarely tested head-to-head. Third, duration of effect remains poorly characterized: even the longer follow-up cohorts in the curated set stop short of the multi-year horizons that an aging-endpoint argument would require.", "This synthesis takes a structured-evidence approach: rather than narratively averaging positive and negative findings, it weights studies by directness to the aging question, separates mechanistic signals from clinical-outcome signals, and surfaces the cross-study disagreements identified across outcome classes. The integrating observation is that the MSC anti-aging case is currently incomplete — positive signals in immune-inflammation and safety-comorbidity coexist with negative and null findings in contextual outcomes, and the boundary conditions under which MSCs might meaningfully extend healthspan have not been established. By foregrounding cross-outcome tensions rather than smoothing them, this synthesis aims to make the evidentiary shape of the field legible to clinicians, regulators, and trial designers. The clinical-versus-mechanistic separation adopted throughout the paper is intended to prevent premature claims about longevity extension while still preserving the plausibility signals that justify further, more rigorously designed trials of MSCs in aging populations.", "The direct evidence establishes what has been observed in human or adjacent clinical settings. The mechanistic evidence helps explain why an effect might be plausible, but it does not by itself establish the size, durability, or safety of a human healthspan effect.", "The study-level structure also prevents selective emphasis. Supportive, null, mixed, and adverse findings remain visible in the same manuscript, allowing the reader to distinguish evidential breadth from evidential certainty.", "The retained Mesenchymal stem cells corpus is reported by outcome class before any cross-domain interpretation. This structure prevents favorable, null, mixed, and adverse evidence from being blended across biologically different endpoints."], "limitations": ["This is an agent-assisted evidence map, not a PRISMA-complete systematic review or clinical guideline.", "It is not PROSPERO-registered and should not be read as medical advice.", "Public sidecars expose citation traces and extraction status; empty fields mean not extracted, not assumed absent."], "publication_id": "4a4ef105-6735-457c-a03e-c95da4a8e083", "screening": {"excluded": 0, "exclusion_reasons": ["No PRISMA full-text exclusion-stage filter was applied."], "flow": ["identified", "screened", "excluded_with_reasons", "included"], "identified": 16, "included": 16, "included_or_retained": 16, "screened": 16, "wording": "16 candidate receipts retained after source retrieval, deduplication, and topic filtering. This is an evidence-map screening trace, not a PRISMA full-text exclusion audit."}}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "4a4ef105-6735-457c-a03e-c95da4a8e083",
  "researka_submission_id": "981aac7f-7cfa-497e-9dc9-ac4adf4aa402",
  "sidecar_name": "contradiction_map.json",
  "sidecar_url": "https://api.researka.org/publications/4a4ef105-6735-457c-a03e-c95da4a8e083/sidecars/contradiction_map.json"
}